- Home
- LIVN vs KNSA Comparison
LIVN vs KNSA Comparison
Compare LIVN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIVN | KNSA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LIVN | KNSA |
|---|---|---|
| Price | $71.99 | $58.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $72.43 | $60.86 |
| AVG Volume (30 Days) | 772.6K | ★ 819.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 0.40 | 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $9.79 | $37.48 |
| Revenue Next Year | $6.63 | $17.87 |
| P/E Ratio | ★ $175.99 | $210.24 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $41.02 | $25.71 |
| 52 Week High | $71.58 | $58.26 |
Technical Indicators
Market Signals| Indicator | LIVN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 71.94 |
| Support Level | $61.24 | $40.67 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.67 | 2.41 |
| MACD | 0.93 | 1.19 |
| Stochastic Oscillator | 97.08 | 98.47 |
Price Performance
Historical ComparisonAbout LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.